Omex 40 mg (Capsule (Enteric Coated))

Unit Price: ৳ 7.02 (20's pack: ৳ 140.40)

Medicine Details

Category	Details
Generic	Omeprazole
Company	Kemiko pharmaceuticals ltd
Also available as	Omex 20 mg capsule Omex 40 mg injection

Treatment of gastric and duodenal ulcer
NSAID-associated duodenal and gastric ulcer
Prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
Gastro-esophageal reflux disease
Long-term management of acid reflux disease
Acid-related dyspepsia
Severe ulcerating reflux esophagitis
Prophylaxis of acid aspiration during general anesthesia
Zollinger-Ellison syndrome
Helicobacter pylori-induced peptic ulcer

Inhibition of gastric acid secretion
Blockage of hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system
Onset of antisecretory effect within one hour
Maximum effect occurring within two hours
Inhibition of secretion lasting up to 72 hours
Gradual return of secretory activity over 3 to 5 days after discontinuation

20 mg once daily for benign gastric and duodenal ulcer
40 mg in severe or recurrent cases of benign gastric and duodenal ulcer
10-20 mg daily for prevention of relapse in duodenal ulcer
20 mg once daily for gastro-esophageal reflux disease
40 mg once daily for 8 weeks in refractory gastro-esophageal reflux disease
10-20 mg daily for long-term management of acid reflux disease
10-20 mg once daily for 2-4 weeks for acid-related dyspepsia
40 mg on the preceding evening and 2-6 hours before surgery for prophylaxis of acid aspiration
60 mg once daily for Zollinger-Ellison syndrome
20 mg twice daily for Helicobacter pylori eradication regimen
10-20 mg once daily for pediatric use in severe ulcerating reflux esophagitis (Child > 1 year)

Intravenous administration only for Omeprazole lyophilized powder and water for injection
Intravenous injection given as a slow intravenous injection
IV infusion given over a period of 20-30 minutes or more
Solution used within 4 hours of reconstitution for IV injection
Solution used within 12 hours when Omeprazole is dissolved in saline and within 6 hours when dissolved in 5% Dextrose for IV infusion
Reconstituted solution should not be mixed or co-administered with any other drug in the same infusion set

Reduced absorption of ketoconazole during Omex treatment
Metabolism in the liver through cytochrome P450
Delayed elimination of diazepam, phenytoin, and warfarin
Increased plasma concentrations during concomitant administration with clarithromycin
No evidence of interaction with phenacetin, theophylline, caffeine, propranolol, metoprolol, cyclosporin, lidocaine, quinidine, estradiol, amoxycillin, or antacids
No effect on absorption by alcohol or food
Useful interaction during H. pylori eradication
Increased bioavailability of digoxin
No evidence of interaction with piroxicam, diclofenac, or naproxen

Known hypersensitivity to Omeprazole
Suspicion of gastric ulcer should exclude possibility of malignancy before treatment

Mild and reversible adverse reactions
Skin rash, urticaria, and pruritus
Photosensitivity, bullous eruption, erythema multiforme, angioedema, and alopecia
Diarrhea and headache, with severe cases requiring therapy discontinuation
Gastrointestinal reactions including constipation, nausea/vomiting, flatulence, and abdominal pain
Dry mouth, stomatitis, and candidiasis
Paraesthesia, dizziness, light headedness, and feeling faint
Somnolence, insomnia, and vertigo
Reversible mental confusion, agitation, depression, and hallucinations in severely ill patients
Arthritic and myalgic symptoms, usually resolving upon therapy cessation
Blurred vision, taste disturbance, peripheral edema, increased sweating, gynaecomastia, and blood disorders
Anaphylactic shock, malaise, fever, bronchospasm, encephalopathy, hepatitis, interstitial nephritis, and hepatic failure
Increases in liver enzymes

No adverse effects of Omeprazole on pregnancy or fetus/newborn child in prospective epidemiological studies
Safe for use during pregnancy
No information on passage into breast milk or effects on the neonate, necessitating discontinuation of breast-feeding if Omeprazole use is essential
Safety and effectiveness not established in pediatric patients <18 years of age